AVIR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.485

+21.25%

-0.530

+32.5%

-0.520

+18.18%

Estimates Revision

The market is revising No Change the revenue expectations for Atea Pharmaceuticals, Inc. (AVIR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 3.45%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.21%

In Past 3 Month

Stock Price

Go Up

+3.45%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Atea Pharmaceuticals Inc (AVIR.O) is -1.58, compared to its 5-year average forward P/E of -59.97. For a more detailed relative valuation and DCF analysis to assess Atea Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-59.97

Current PE

-1.58

Overvalued PE

249.76

Undervalued PE

-369.71

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

6.87

Current EV/EBITDA

0.53

Overvalued EV/EBITDA

28.47

Undervalued EV/EBITDA

-14.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.46

Current PS

0.00

Overvalued PS

22.05

Undervalued PS

-7.13

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AVIR News & Events

Events Timeline

No data

News

1.0

09-02Newsfilter

Atea Pharmaceuticals to Showcase at the 23rd Annual Global Healthcare Conference Hosted by Morgan Stanley

9.5

08-07NASDAQ.COM

Atea (AVIR) Q2 Loss Narrows 8%

9.0

06-24NASDAQ.COM

Atea Pharmaceuticals Launches Phase 3 C-FORWARD Trial for HCV Treatment Regimen Combining Bemnifosbuvir and Ruzasvir

People Also Watch

Frequently Asked Questions

What is Atea Pharmaceuticals Inc (AVIR) stock price today?

The current price of AVIR is 3.145 USD — it has decreased -0.16 % in the last trading day.

What is Atea Pharmaceuticals Inc (AVIR)'s business?

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

What is the price predicton of AVIR Stock?

Wall Street analysts forecast AVIR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVIR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Atea Pharmaceuticals Inc (AVIR)'s revenue for the last quarter?

Atea Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Atea Pharmaceuticals Inc (AVIR)'s earnings per share (EPS) for the last quarter?

Atea Pharmaceuticals Inc. EPS for the last quarter amounts to -0.53 USD, increased 43.24 % YoY.

What changes have occurred in the market's expectations for Atea Pharmaceuticals Inc (AVIR)'s fundamentals?

How many employees does Atea Pharmaceuticals Inc (AVIR). have?

Atea Pharmaceuticals Inc (AVIR) has 56 emplpoyees as of December 15 2025.

What is Atea Pharmaceuticals Inc (AVIR) market cap?

Today AVIR has the market capitalization of 246.10M USD.